Journal for ImmunoTherapy of Cancer (Nov 2023)
1147-E UI-101, a TLR7/8 agonist encapsulated in cholesteryl pullulan nanoparticle targeting tumor-associated macrophages via binding to DC-SIGN, elicits potent anti-tumor immunity without severe side effect
Abstract
No abstracts available.